Abstract
Estrogen (17β-estradiol) is essential for normal growth and differentiation in the mammary gland. In the last three decades, previous investigations have revealed that Estrogen Receptor Alpha (ERα) plays a critical role in breast cancer. More recently, observations regarding the widespread expression of ERβ-like proteins in normal and neoplastic mammary tissues have suggested that ERβ is also involved in the mentioned pathology. Design of new drugs both steroidal and nonsteroidal that target any of these receptors represents a promise to treat breast cancer although it remains a challenge due to the sequence similarity between their catalytic domains.
In this work, we propose a new set of compounds that could effectively target the estrogen receptors ERα and ERβ. These ligands were designed based on the chemical structure of the ERβ-selective agonist Diarylpropionitrile (DPN). The designed ligands were submitted to in silico ADMET studies, yielding in a filtered list of ligands that showed better drug-like properties. Molecular dynamics simulations of both estrogen receptors and docking analysis were carried-out employing the designed compounds, from which two were chosen due to their promising characteristics retrieved from theoretical results (docking analysis or targeting receptor predictions). They were chemically synthetized and during the process, two precursor ligands were also obtained.
These four ligands were subjected to biological studies from which it could be detected that compound mol60b dislplayed inhibitory activity and its ability to activate the transcription via an estrogenic mechanism of action was also determined. Interestinly, this observation can be related to theoretical binding free energy calculations, where the complex: ERβ-mol60b showed the highest energy ΔGbind value in comparison to others.
Keywords: Estrogen receptor, affinity, breast cancer, docking analysis, analogues, anti-proliferative.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand
Volume: 18 Issue: 11
Author(s): M. Martinez-Archundia*, J.B. García-Vázquez, B. Colin-Astudillo, M. Bello, B. Prestegui-Martel, A. Chavez-Blanco, A. Dueñas-González, M.J. Fragoso-Vázquez, J. Mendieta-Wejebe, E. Abarca-Rojano, D. Ordaz-Rosado, R. García-Becerra, D. Castillo-Bautista and J. Correa Basurto
Affiliation:
- Laboratorio de Modelado Molecular, Bioinformatica y diseno de farmacos, Seccion de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Plan de San Luis y Díaz Miron S/N, Col, Casco de Santo Tomas, Mexico City, 11340 MX,Mexico
Keywords: Estrogen receptor, affinity, breast cancer, docking analysis, analogues, anti-proliferative.
Abstract: Estrogen (17β-estradiol) is essential for normal growth and differentiation in the mammary gland. In the last three decades, previous investigations have revealed that Estrogen Receptor Alpha (ERα) plays a critical role in breast cancer. More recently, observations regarding the widespread expression of ERβ-like proteins in normal and neoplastic mammary tissues have suggested that ERβ is also involved in the mentioned pathology. Design of new drugs both steroidal and nonsteroidal that target any of these receptors represents a promise to treat breast cancer although it remains a challenge due to the sequence similarity between their catalytic domains.
In this work, we propose a new set of compounds that could effectively target the estrogen receptors ERα and ERβ. These ligands were designed based on the chemical structure of the ERβ-selective agonist Diarylpropionitrile (DPN). The designed ligands were submitted to in silico ADMET studies, yielding in a filtered list of ligands that showed better drug-like properties. Molecular dynamics simulations of both estrogen receptors and docking analysis were carried-out employing the designed compounds, from which two were chosen due to their promising characteristics retrieved from theoretical results (docking analysis or targeting receptor predictions). They were chemically synthetized and during the process, two precursor ligands were also obtained.
These four ligands were subjected to biological studies from which it could be detected that compound mol60b dislplayed inhibitory activity and its ability to activate the transcription via an estrogenic mechanism of action was also determined. Interestinly, this observation can be related to theoretical binding free energy calculations, where the complex: ERβ-mol60b showed the highest energy ΔGbind value in comparison to others.
Export Options
About this article
Cite this article as:
Martinez-Archundia M.*, García-Vázquez J.B., Colin-Astudillo B., Bello M. , Prestegui-Martel B. , Chavez-Blanco A. , Dueñas-González A. , Fragoso-Vázquez M.J., Mendieta-Wejebe J. , Abarca-Rojano E. , Ordaz-Rosado D. , García-Becerra R., Castillo-Bautista D. and Correa Basurto J., Computational Study of the Binding Modes of Diverse DPN Analogues on Estrogen Receptors (ER) and the Biological Evaluation of a New Potential Antiestrogenic Ligand, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (11) . https://dx.doi.org/10.2174/1871520618666171129152953
DOI https://dx.doi.org/10.2174/1871520618666171129152953 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Erbin, a Negative Regulator in Diverse Signal Pathways
Current Protein & Peptide Science Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients
Current Medicinal Chemistry Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres
Current Pharmaceutical Design Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging
Mini-Reviews in Medicinal Chemistry MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Anti-Fungal Activity of <i>Cressa cretica, Leptadenia pyrotechnica</i> and <i>Pulicaria crispa</i>, Indigenous Plants of Cholistan Desert, Pakistan
Anti-Infective Agents Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry RNA Splicing: Basic Aspects Underlie Antitumor Targeting
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology